Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...
GlobalData on MSN9d
EC approves GSK’s Jemperli-chemo combo for endometrial cancerThe EC has approved GSK's Jemperli (dostarlimab) combined with chemotherapy for primary advanced or recurrent endometrial ...
GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...
GSK (GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. Read more here.
London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...
Zacks.com on MSN9d
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial CancerGSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus ...
Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...
European Commission approved GSK's Jemperli with chemotherapy for advanced or recurrent endometrial cancer, covering 75% of cases. RUBY trial showed Jemperli combo reduced death risk by 31% and ...
today announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback